DANVILLE, Calif.--(BUSINESS WIRE)--VasoStitch, a start-up medical technology company, announced today that it has successfully completed its first in vivo study of its percutaneous access-and-closure system for the nonsurgical deployment of large-diameter transcatheter therapeutic devices, such as Transcatheter Aortic Valve Implants (TAVI) and Endovascular Aneurysm Repair (EVAR) devices. The VasoStitch system is designed to reduce procedural complexity and eliminate the need for an “open” surgical procedure.
